Introduction

Mammalian oocytes and early embryos are surrounded by a glycoprotein matrix referred to as the zona pellucida (ZP) [1]. Proteolytic enzymes digest the ZP progressively under specific physiological conditions thus causing it to get thinner as the embryo develops. This goes on until the embryo hatches from ZP to complete implantation [2, 3]. However, in in vitro culture or cryopreservation, a thick or hardened ZP impairs hatching of the human embryo [4, 5]. Various assisted hatching (AH) techniques have been introduced since the advent of mechanical AH to overcome these obstacles [6]. AH can be accomplished through thinning of the ZP using acidified Tyrode’s solution, laser, ZP drilling, two or three-dimensional partial zona dissection using a glass microneedle or a piezo-micromanipulator [7,8,9]. However, the success of AH is dependent on the method used as well as the extent the AH is done [10].

Laser-assisted hatching (LAH) is a common AH method because of its advantages which include short exposure time, simple operation, accurate positioning, indirect contact, safety, and effectiveness [11]. Zona drilling and zona thinning are the two most frequently used LAH methods in clinical practice. On one hand, zona drilling creates a single full-thickness hole in the ZP that breaks the inner membrane. On the other hand, zona thinning thins a considerable area of the outer ZP layer while keeping the inner layer intact [12]. As such, it poses fewer risks to the embryo compared to zona drilling because there is no hole through which blastomeres can potentially escape or get trapped [13]. Nonetheless, it is still unclear which method provides the best clinical outcomes despite numerous studies comparing the benefits of the two methods. Some studies suggest that T-LAH results in significantly better pregnancy outcomes in human 8-cell embryos compared to D-LAH [14]. Contrary to these findings, Shubhashree et al reported that zona thinning at the 8-cell stage in mouse embryos does not assist nor promote hatching in vitro [15]. Most studies compare the clinical effects of assisted incubation and non-assisted incubation, or different assisted incubation methods in the whole infertile population without reporting the populations that benefit from different laser-assisted incubation methods [8]. Herein, the clinical outcomes of T-LAH and D-LAH in day four (D4) frozen-embryo-transfer (FET) cycles were investigated. The effects of the different LAH methods at different embryo ages were also assessed in the context of previously failed cycles and cases of increased endometrial thickness.

Materials and methods

Patients’ characteristics

Clinical data from 11471 infertile patients who underwent FET cycles between January 2014 and October 2018 at the department of reproductive medicine of Guangdong Women and Children hospital was analyzed. Patients included in the study were those aged between 22 and 47 years, had undergone Day 4 frozen-thawed embryo transfer, had a maximum of four previous failed IVF-ET procedures, and whose all embryo transfers had been performed using embryos at the morula or cleavage-stage (blastomeres continued to grow after thawing). Finally, only 1410 patients comprising 2915 embryos were included. All the 2915 embryos were frozen on day 3 in vitrification cryopreservation. The 1410 patients were classified into 2 groups based on the laser-assisted hatching method: the thinning laser-assisted hatching group (T-LAH, 716 patients) and the drilling laser-assisted hatching group (D-LAH, 694 patients). This study was approved by the Ethics Committee of Guangdong Women and Children Hospital. All participants provided a written informed consent prior to the study.

Controlled ovarian hyperstimulation

Patients in both groups underwent controlled ovarian stimulation (COS) using the standard long protocol or the antagonist protocol. The long protocol was administered using GnRHa (1.0–1.2 mg Diphereline) based on the patients’ body mass index during their previous menstruation mid-luteal phase. After 2 weeks, the patients were stimulated using Gn (recombinant human FSH: 100–300 IU). Patients treated using the antagonist protocol were directly treated with Gn from the second to the fifth day of menstruation during the basal follicular phase of ovarian stimulation. Gn doses were adjusted based on ultrasound monitoring and serum E2, LH, and FSH levels. An antagonist (Ghani Rick 0.25 mg) was administered four day post Gn treatment. Patients were treated with human chorionic gonadotropin (hCG; 5,000–10,000 IU) to induce oocyte maturation when a significant number of the follicles reached 16–18 mm. Transvaginal follicular aspiration was then performed 34–36 h later. Regular IVF/ICSI were conducted based on the response of the patients.

Embryo selection and transfer

Embryos were transferred on day 2 of thawing. Cleavage stage embryos were graded based on the scoring system of the society for assisted reproductive technology (SART). More than 5 cells with a fragmentation rate of less than 25% were cryopreserved. Embryos were thawed and cultured overnight at 37 °C and 6% CO2 before transplantation. Incubation was then done overnight to observe embryo development. Ultrasound scans were also performed to monitor the urinary LH levels of patients with natural ovulation. The freeze-thawed embryos were transplanted on the 3rd day of ovulation (on which the endometrium thickness ≥ 5 mm). Hormone replacement treatment was done in patients without natural ovulation or with irregular menstrual cycles. Estradiol valerate (2–4 mg/day) was prescribed to be taken from the 3rd day of the menstrual cycle. Moreover, the patients were injected with progesterone (80 mg/day) from day 8 to 10. Ultrasound guided embryo transplant was subsequently done on day 11 to 15.

Freezing and thawing

Freezing and thawing of the embryos was done using previously established protocols [16]. For freezing, the embryos were transferred from the culture media to the basal media (BM) containing HEPES (Quinn’s SAGE, ART-1024) and supplemented with human serum albumin (20% v/v) (HAS, Vitrolife, 10064). The embryos were then transferred to the vitrification solution 1 (BM solution supplemented with DMSO (7.5% v/v) and ethylene glycol (7.5% v/v)) for 2–7 min. They were then transferred to the vitrification solution 2 (BM solution added DMSO (15% v/v), ethylene glycol (15% v/v), and sucrose (10% v/v)) for 30 seconds when shrank to 80%. They were then collected within 5–10 s in a minimal volume and transferred into a cryo device for immediate preservation in liquid nitrogen.

For thawing, the embryos were transferred from the cryo device to warming solution 1 (BM solution added 1 M sucrose) for 1 min and then to warming solution 2 (BM solution added 0.5 M sucrose) for 3 min. They were then transferred to basal medium for 5 min, washed using G2 solution and cultured overnight at 37 °C and 6% CO2.

Laser-assisted hatching procedure

Laser-assisted hatching was performed using a Zona infrared laser optical system (ZILOS-tk®, Hamilton-Thorne Instruments Biosciences). LYKOS is a unique system in which the laser is built into the objective lens. The system relies on a confocal laser with optical imaging, a 40× objective lens, and 0.6NA. Embryos were exposed to a 1.48-μm wavelength diode laser target positioned to puncture the ZP at the clear space between the inner membrane of the ZP and the blastomere. The positioning ensured that the blastomere was not on the laser path. Few laser pulses at the lowest possible power level were used to limit injury to the blastomeres. The applied laser energy was regulated by controlling the pulse duration of the laser. The pulse width of the laser was set at 25 ns and the typical pulse energy at 300 mJ/pulse. The power of the laser was 100%. Embryos were manipulated in their original culture medium in embryo culture dishes put on the displacement stage of a Diaphot Inverted Microscope. T-LAH was conducted using 5–8 ablations of 2.8 ms successively applied around the ZP. This began at one point and continued until the thickness of the ZP was reduced by 60–80% in 25% of the ZP circumference (Fig. 1b). In the same line, D-LAH was performed using a laser pulse length of 0.450-0.650 ms that made a 40-μm diameter hole in the ZP (Fig. 1c). The culture medium was changed after the procedure. All embryos underwent laser-assisted hatching 2 h before transplantation on the morning of D4.

Fig. 1
figure 1

Laser-assisted hatching procedure of vitrified-thawed D4 embryos. a D4 morula embryos (non-LAH). b T-LAH: ZP was subjected to laser treatment from the outside to the inside until the thickness of the ZP was reduced by 60–80% (represented by the double-ended black arrow) in 25% of the ZP circumference (represented by the double-ended white arrow) c D-LAH: ZP was subjected to laser treatment and a 40-μm diameter hole made (represented by the double-ended white arrow)

Evaluation of clinical outcomes

Clinical pregnancy was determined 4 weeks after embryo transfer through an ultrasound scan. Pregnancy was confirmed if at least one gestational sac was observed, and embryo heart activity was detected. The pregnancy rate was defined as the percentage of ET cycles resulting in pregnancy. The implantation rate was defined as the percentage of gestational sacs of the total number of embryos transferred. The rate of live birth was defined as the proportion of patients with live births among the total transfer cycles. The rate of miscarriage was defined as the number of patients with a miscarriage amongst patients who attained clinical pregnancy.

Data analysis

All statistical analyses were done using Statistical Product and Service Solutions (SPSS) version 19.0. Data was presented as means ± standard error. χ2 analysis was used to compare implantation rates between groups. In the same line, the F test was used to determine the homogeneity of variance. The independent samples t test equal variance while the non-parametric test determined the unequal variance. P values less than 0.05 (P < 0.05) indicated that there were significant differences between groups.

Results

Clinical outcomes of T-LAH vs D-LAH

The basic parameters evaluated using both methods are shown in Table 1. There were no significant differences between the T-LAH and D-LAH group in terms of average age, infertility duration, infertility type, endometrial thickness, the number of transferred embryos, number of previously failed cycles, and embryo survival (P > 0.05). Implantation rates and the rates of clinical pregnancies were significantly higher in the T-LAH group(32.73%, 50.98%)compared to those in the D-LAH group (29.09%, 43.95%) (P < 0.05 and P < 0.01, respectively; Table 2). In the same line, the rate of live births was slightly higher in the T-LAH although the difference was statistically insignificant (P > 0.05). In addition, there were no significant differences between the T-LAH and D-LAH group in terms of miscarriages (17.53% vs 13.77%), multiple pregnancies (31.51% vs 34.42%), ectopic pregnancies (3.01% vs 2.62%), preterm births (28.21% vs 32.03%), and birth defects (2.14% vs 1.17%) (P > 0.05; Table 2).

Table 1 Clinical and laboratory characteristics of the patients in the T-LAH and D-LAH
Table 2 Pregnancy outcomes for T-LAH and D-LAH

Comparison of the clinical outcomes across different ages

Comparisons of clinical outcomes among patients of different ages revealed that the rates of implantation and clinical pregnancy were significantly higher in patients aged < 35 years in the T-LAH group (38.35%, 58.04%) compared to those of the same age bracket in the D-LAH group (33.33%, 49.25%) (P < 0.05). However, there were no marked significant differences in rates of live birth, miscarriage, and multiple pregnancies (P > 0.05) between the groups. Moreover, there were no significant differences in the rates of implantation, clinical pregnancies, live births, miscarriages, and multiple pregnancies in patients aged ≥35 between the two groups (Table 3).

Table 3 Pregnancy outcomes related to age

Comparison of clinical outcomes in the context of previously failed cycles

Patients were further categorized into two: those receiving the 1st transfer cycle, and those with ≥1 previously failed transfer cycle (Table 4). There were no significant differences between the 2 groups in the rates of implantation, clinical pregnancies, live births, miscarriages, and multiple pregnancies in patients receiving the first transfer cycle (P > 0.05). However, in the group with ≥1 previously failed cycles, patients undergoing T-LAH had significantly higher rates of implantation and clinical pregnancies (30.26%, 48.65%) compared with those in the D-LAH group (25.46%, 40.48%; P < 0.05). Moreover, there were no significant differences in the rates of live births, miscarriages, and multiple pregnancies in patients with ≥1 previously failed cycle in both groups.

Table 4 Pregnancy outcomes related to previous failed cycle

Comparison of the clinical outcomes in different endometrial thickness

Endometrial thickness was classified as E1 (<8 mm), E2 (8–10 mm), and E3 (> 10 mm) (Table 5). Implantation and clinical pregnancy rates were significantly higher in E2 patients of the T-LAH group (33.01%, 52.46%) than those of E2 patients in the D-LAH group (28.70%, 43.58%) (P < 0.05 and P < 0.01). However, E2 patients in both groups had insignificant differences in the rates of live births, miscarriages, and multiple pregnancies (P > 0.05). E1 and E3 patients in both groups had insignificant differences in all clinical outcomes (P > 0.05).

Table 5 Pregnancy outcomes related to endometrial thickness

Discussion

Vitrification procedures cause hardening of the zona pellucida (ZP) thereby leading to hatching difficulties [17]. Zona thickness is negatively associated with embryo implantation [18]. Assisted hatching improves implantation rates during assisted reproduction [19]. Laser-assisted hatching through zona drilling or thinning significantly increases implantation and clinical pregnancy rates [17, 20]. However, data regarding the approach that provides better clinical outcomes is lacking. Whether the two methods can be used interchangeably in Day4, FET remains unclear. Herein, clinical outcomes in D4 frozen-thawed embryos treated using T-LAH and D-LAH were analyzed. T-LAH treatment resulted in higher rates and significantly higher clinical pregnancy rates compared with D-LAH treatment. Moreover, T-LAH treatment resulted in slightly higher live birth rates compared with D-LAH treatment. However, the two approaches had no significant differences in the rates of miscarriages, multiple pregnancies, ectopic pregnancies, preterm births, and congenital disabilities. These findings suggested that patients who underwent T-LAH had better clinical outcomes.

The clinical effects of T-LAH and D-LAH at various ages, frozen embryo transfer cycles, and endometrial thicknesses were also further analyzed. The physiological embryo hatching process can be explained using two theories [21]. The first theory postulates that the digestive enzymes that degrade the ZP mediate embryo hatching [22]. The second theory postulates that embryo hatching results from physical pressure from the proliferating blastomere and the associated expansion and contraction of the blastocoel cavity [23]. ZP thickness varies in infertile women. Moreover, the in vitro culture environment influences the thickness of ZP. Long co-incubation periods generate elevated levels of reactive oxygen species which damage the embryos by hardening the ZP. This in turn affects embryo development [24]. In addition, embryo freezing and thawing, female age, embryo quality, and culture medium affect the texture of ZP and prevent embryo hatching and implantation [25]. Successful implantation requires synchronous development of both the embryo and the endometrium. These happenings cause the embryo to express and secret multiple factors that promote its attachment to the endometrium via the ZP thereby improving the clinical outcomes [26]. As such, a systematic clinical analysis is required to determine which method(s) has optimal clinical outcomes.

The efficiency of ZP thinning decreases significantly with advancing age thereby reducing the implantation rates [27]. LAH is conducted on frozen embryos before FET to reverse the adverse effects of zona hardening and improve the chances of successful pregnancy [28]. Nonetheless, some studies report that assisted hatching does not improve reproductive outcomes in advanced maternal age [29]. These contradictory results are attributed to the use of different sample sizes or different assisted hatching methods [30]. The Chinese Society of Reproductive Medicine (CSRM) data suggest that more than 70% of patients receiving assisted reproductive technology (ART) treatment in China are aged below 35 years [31]. In the same line, the US CDC report indicates that majority of patients receiving infertility treatment are aged below 35 years old (38.3%) and between 35 and 37 years (21.5%) [32]. These reports indicate that the rate of infertility among the young people in China is higher than that of USA. It is widely known that age is an independent risk factor for female fertility and pregnancy outcome. The ovarian function usually has a significant downward trend from the age of 35 [33]. The Chinese practice guideline on ART strategies for women with advanced age use 35 years as the dividing line for female infertility patients; older patients are generally defined as those aged above 35 years [34]. Herein, the rates of implantation and clinical pregnancy in patients aged below 35 years were significantly higher in the T-LAH group (38.4%, 58.0%) compared to those of the D-LAH group (33.3%, 49.3%) (P < 0.05) . Similar trends were observed in patients aged 35 years and older though the differences were insignificant.

Hardening of the ZP and embryo hatching difficulties causes poor pregnancy outcomes in patients with multiple implantation failures even in the absence of other additional factors [35]. These implantation failures result from poor embryo-endometrial synchronous FET [36]. AH is beneficial to patients with a history of implantation failures. The patients undergo fresh cleavage-stage embryo transfer [37]. Successful implantation needs synchronous development of the embryo and the endometrium. AH prolong the interaction time between embryo and endometrium thereby improving embryo attachment to the endometrium. LAH through ZP thinning significantly enhances the clinical outcomes by improving the rates of implantation and clinical pregnancies FET among patients with recurrent failure [38]. Herein, patients with previously failed implantation of D4 frozen-thawed cycles exhibited higher implantation and clinical pregnancy rates with T-LAH treatment compared to D-LAH treatment. This implied that T-LAH confers beneficial clinical outcomes for D4 vitrified-warmed embryos. However, there were no significant differences between the outcomes of the two approaches for patients undergoing first embryo transfer cycles. Analysis of the clinical outcomes in the context of varied endometrial thicknesses further revealed that patients with an endometrial thickness of 8–10 mm had significant improvements in implantation and clinical pregnancy rates under T-LAH treatment compared to D-LAH treatment. This strongly suggested that T-LAH treatment is superior to D-LAH treatment.

Similar studies using mouse models report that zona thinning at the 8-cell stage does not aid nor promote hatching in vitro [15]. However, it is unclear whether human embryos behave in a similar manner under similar conditions. Honguntikar, S. D. et al reported that laser manipulation (zona opening) significantly enabled blastocyst hatching. However, DNA damage in laser-hatched embryos affected implantation and post-implantation development [39]. Given that the ZP inner membrane is broken to designate a full-thickness opening, the embryos can suffer sudden change in the biochemical environment with limited time for adaptive changes, are at a higher risk of contracting a bacterial infection or immunologic aggression, and the blastomere can be easily lost through the hole or separation/splitting thereby causing monozygotic twinning [20]. Herein, clinical merits and demerits of applying either of the two methods were critically analyzed. Evidently, T-LAH significantly improved the clinical outcomes of the patients compared to D-LAH. This was notably observed in implantation and clinical pregnancy rates in D4 FET cycles among patients aged <35 years with previous implantation failures (≥1 cycles) as well as those with an excellent endometrial thickness (8–10 mm). This phenomenon was hypothesized to have been influenced by two factors. DNA damage to the laser-hatched embryos negatively affected their implantation and post-implantation development despite the zona opening having better hatchability and survival rate than zona thinning. Moreover, thinning caused the embryos to express and secrete multiple factors which promoted their attachment to the endometrium. Nonetheless, further studies should be conducted to test these hypotheses.

In the same line, the rate of live births was slightly higher in the T-LAH group compared to the D-LAH group (39.11% vs. 36.89%). However, the difference was insignificant. Similarly, there were no significant differences between the T-LAH and D-LAH group in terms of adverse effects during pregnancy and newborns. This finding further affirmed that thinning is a safe and feasible approach for assisted hatching.

Nevertheless, this study was limited by lack of embryo hatching rates of the two groups. Cognizant to this, comprehensive prospective studies should be conducted in the future to comprehensively explore the clinical outcomes of the two LAH methods.

Conclusion

This study systematically analyzed the clinical effects of two assisted incubation methods in populations of different ages. T-LAH was found to be superior to D-LAH in improving clinical implantation and pregnancy outcomes in D4 FET, particularly in patients aged less than 35 years with at least one previously failed cycle or an endometrial thickness of 8–10 mm. The findings of this study provide theoretical support for clinical individualized diagnosis and treatment of patients with infertility.